Evaluation of Anticancer Therapy-Related Tumor Flare Reaction: Insights From Food and Drug Administration's Adverse Event Reporting System Dataset - PubMed
3 days ago
- #Tumor Flare Reaction
- #Anticancer Therapy
- #FAERS Database
- Study evaluates tumor flare reaction (TFR) linked to anticancer therapy using FAERS database.
- 566 TFR cases recorded from Q1 2004 to Q3 2024, with peak incidence in 2023.
- 28 anticancer drugs strongly associated with TFR, only 4 mentioned in medication instructions.
- Lenalidomide most frequent drug causing TFR, accounting for 38% of reports.
- Targeted therapies like Rituximab not explicitly marked for TFR in FAERS.
- Clinicians advised to monitor TFR closely and improve therapeutic strategies.